TMC435 in Patients Infected with HCV Genotype 1 Who Have Failed Previous Pegylated Interferon/Ribavirin Treatment: Virologic Analyses of The ASPIRE Trial

被引：0
|
作者：
Picchio, Gaston
Lenz, Oliver
Fevery, Bart
Vijgen, Leen
Verbeeck, Jannick
Peeters, Monika
Beumont-Mauviel, Maria
Zeuzem, Stefan
机构：
来源：
GASTROENTEROLOGY | 2012年 / 142卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S145 / S145
页数：1
相关论文
共 50 条
  • [41] Pegylated Interferon (alpha-2B) and ribavirin (Rebetol) for the treatment of HCV infected patients who failed prior therapy: Sustained response data
    Gaglio, PJ
    Choi, J
    Zimmerman, D
    Heller, L
    Brown, RS
    GASTROENTEROLOGY, 2004, 126 (04) : A721 - A721
  • [42] Correlations between rapid virologic response, early virologic response and sustained virologic response in HCV genotype 1 patients treated with pegylated interferon alfa-2a and ribavirin
    Reddy, KR
    Rakela, J
    Lopez-Talavera, JC
    Pockros, PJ
    GASTROENTEROLOGY, 2005, 128 (04) : A718 - A718
  • [43] VIROLOGIC ANALYSIS OF GENOTYPE-1-INFECTED PATIENTS TREATED WITH ONCE-DAILY TMC435 DURING THE OPTIMAL PROTEASE INHIBITOR ENHANCEMENT OF RESPONSE TO THERAPY (OPERA)-1 STUDY
    Lenz, Oliver
    Vijgen, Leen
    Lin, Tse-I
    Peeters, Monika
    De Smedt, Goedele
    Picchio, Gaston
    HEPATOLOGY, 2010, 52 (04) : 709A - 709A
  • [44] High sustained virological response (SVR) with pegylated interferon/ribavirin (PEG/RBV) in chronic HCV patients who have previously failed standard interferon regimes
    Wilson, J. L.
    Mellor, K.
    Campbell, B.
    Thompson, A. J. V.
    Demediuk, B.
    Shaw, G.
    Watson, K. J. R.
    Bell, S.
    Desmond, P. V.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A311 - A311
  • [45] VIROLOGIC RESPONSE RATES FOLLOWING 4 WEEKS OF FILIBUVIR IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN CHRONICALLY-INFECTED HCV GENOTYPE-1 PATIENTS
    Jacobson, I.
    Pockros, P. J.
    Lalezari, J.
    Lawitz, E.
    Rodriguez-Torres, M.
    DeJesus, E.
    Haas, F.
    Martorell, C.
    Pruitt, R.
    Purohit, V.
    Srinivasan, S.
    Jagannatha, S.
    Rana, K.
    Hammond, J.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S465 - S465
  • [46] Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin
    Bonardi, Renato
    Tabone, Marco
    Manca, Aldo
    Pellicano, Rinaldo
    Ciancio, Alessia
    Rizzetto, Mario
    BIOMEDICINE & PHARMACOTHERAPY, 2011, 65 (04) : 303 - 306
  • [47] EFFICACY AND SAFETY OF TMC435 IN COMBINATION WITH PEGINTERFERON α-2A AND RIBAVIRIN IN TREATMENT-NAiVE GENOTYPE-1 HCV PATIENTS: 24-WEEK INTERIM RESULTS FROM THE PILLAR STUDY
    Fried, Michael W.
    Buti, Maria
    Dore, Gregory J.
    Ferenci, Peter
    Jacobson, Ira
    Marcellin, Patrick
    Zeuzem, Stefan
    Lenz, Oliver
    Peeters, Monika
    Sekar, Vanitha J.
    De Smedt, Goedele
    HEPATOLOGY, 2010, 52 (04) : 403A - 404A
  • [48] Hispanic patients with genotype 2 or 3 chronic hepatitis C have lower rates of sustained virologic response to treatment with pegylated interferon and ribavirin
    Douglass, Jeff
    Qualls, Clifford
    Wiggins, Charles
    Dunkelberg, Jeff
    Arora, Sanjeev
    GASTROENTEROLOGY, 2006, 130 (04) : A770 - A770
  • [49] Pegylated interferon alpha 2b and Ribavirin for HCV infected patients who failed prior therapy: Interim sustained response data.
    Gaglio, PJ
    Brown, M
    Zimmerman, D
    Choi, J
    Dove, L
    Brown, RS
    HEPATOLOGY, 2002, 36 (04) : 575A - 575A
  • [50] Interferon alpha plus ribavirin treatment in relapsers chronic HCV patients infected with genotype 1b.
    Calleja, JL
    Domper, F
    Albillos, A
    Martinez, JL
    Vera, MI
    Barrios, C
    Escartin, P
    HEPATOLOGY, 1998, 28 (04) : 211A - 211A
12345